The drugmaker filed for Chapter 11 bankruptcy protection in Delaware June 10. The court documents listed $175.1 million in assets and $262.5 million in liabilities.
The Chapter 11 protection will allow the company to keep operating while it comes up with a plan to pay the settlement.
“After conducting a thorough review of available strategic alternatives, we determined that a court-supervised sale process is the best course of action to maximize the value of our assets and address our legacy legal challenges in a fair and transparent manner,” CEO Andrew Long told Bloomberg.
Insys is the first drugamaker to file for bankruptcy protection as a result of opioid litigation.
The bankruptcy filing comes a month after Insys founder John Kapoor and four former executives were convicted in a racketeering conspiracy to bribe physicians and boost prescriptions of its fentanyl spray, Subsys.
More articles on pharmacy:
Viewpoint: The $2.1M drug price record won’t last long
Purdue Pharma hit with 4 more opioid lawsuits: 4 things to know
EpiPen shortage will drag on: 4 things to know
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
